

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2696)

INSIDE INFORMATION ANNOUNCEMENT POSITIVE PROFIT ALERT

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the Group’s unaudited consolidated management accounts for the six months ended 30 June 2023 (the “**Reporting Period**”) and the information currently available to the Board, it is expected that the Group will record a profit for the period of approximately RMB200 million for the Reporting Period, as compared to the loss for the period of approximately RMB252.1 million for the six months ended 30 June 2022. This is the first time for the Group to achieve half-year profits.

The turnaround from loss to profit of the Group during the Reporting Period is mainly attributable to:

- HANQUYOU, the core product of the Group, of which the number of patients has continued to grow, and the profitability of HANQUYOU has been enhanced during the Reporting Period.
- HANSIZHUANG, the innovative product of the Group, of which the sales revenue has continued to increase since its approval for marketing in March 2022.
- The Group continued to strengthen its meticulous management measures and achieved results in respect of cost control.

As the Company is still in the course of finalizing the results of the Group for the Reporting Period, the information contained in this announcement is only based on the preliminary assessment made by the Board with reference to the Group's unaudited consolidated management accounts for the Reporting Period and the information currently available to the Board, which has neither been reviewed nor confirmed by the auditors of the Company or the audit committee of the Board. Shareholders and potential investors are advised to refer to the Group's interim results announcement for the Reporting Period which is expected to be published in August 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 3 July 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive Directors.